Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
57 studies found for:    "Multiple Sclerosis, Chronic Progressive"
Show Display Options
Rank Status Study
1 Completed Efficacy of Cyclophosphamide Versus Methylprednisolone in Patients With Secondary Progressive Multiple Sclerosis
Condition: Multiple Sclerosis, Chronic Progressive
Interventions: Drug: Cyclophosphamide (drug);   Drug: Methylprednisolone (drug)
2 Active, not recruiting Lipoic Acid for Secondary Progressive Multiple Sclerosis (MS)
Condition: Multiple Sclerosis, Chronic Progressive
Interventions: Drug: lipoic acid;   Drug: Placebo
3 Unknown  Safety Study of RTL1000 (Recombinant T Cell Receptor Ligand) in Subjects With Multiple Sclerosis
Conditions: Multiple Sclerosis, Chronic Progressive;   Multiple Sclerosis, Relapsing-Remitting
Interventions: Drug: RTL1000 (recombinant T cell receptor ligand);   Drug: RTL1000 Placebo
4 Unknown  Evaluation of Efficiency of Ritalin in Multiple Sclerosis (MS) Patients
Conditions: Relapsing Remitting Multiple Sclerosis;   Multiple Sclerosis, Chronic Progressive
Intervention: Drug: Ritalin
5 Active, not recruiting China Betaferon Adherence, Coping and Nurse Support Study
Condition: Multiple Sclerosis, Chronic Progressive
Intervention: Drug: Interferon beta-1b (Betaseron, BAY86-5046)
6 Completed Safety Study of an Immunomodulating Microparticle to Treat Progressive Multiple Sclerosis
Conditions: Secondary Progressive Multiple Sclerosis;   Primary Progressive Multiple Sclerosis
Intervention: Biological: MIS416
7 Active, not recruiting Sunphenon in Progressive Forms of Multiple Sclerosis
Condition: Multiple Sclerosis
Interventions: Drug: Sunphenon EGCG;   Drug: Placebo
8 Recruiting Open-Label Study to Evaluate the Efficacy of ECP in Secondary Progressive Multiple Sclerosis
Condition: Secondary Progressive Multiple Sclerosis
Interventions: Drug: SoluMedrol;   Device: Extracorporeal Photopheresis
9 Active, not recruiting A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
Condition: Multiple Sclerosis, Primary Progressive
Interventions: Drug: methylprednisolone;   Drug: ocrelizumab;   Drug: Placebo
10 Withdrawn Dose Escalation Study to Evaluate the Penetration and Pharmacodynamic Effects of Baminercept in the Cerebrospinal Fluid (CSF)and Safety in Subjects With Secondary Progressive Multiple Sclerosis (SPMS)
Condition: Secondary Progressive Multiple Sclerosis
Interventions: Biological: Placebo;   Biological: Baminercept
11 Recruiting Estriol Treatment in Multiple Sclerosis (MS): Effect on Cognition
Conditions: Relapsing-remitting Multiple Sclerosis;   Secondary-progressive Multiple Sclerosis;   Primary-progressive Multiple Sclerosis
Interventions: Drug: estriol;   Other: Placebo;   Drug: Norethindrone;   Other: Progestin Placebo
12 Completed Autologous Mesenchymal Stem Cell (MSC) Transplantation in MS
Conditions: Relapsing-Remitting Multiple Sclerosis;   Secondary Progressive Multiple Sclerosis;   Progressive Relapsing Multiple Sclerosis
Intervention: Biological: Autologous mesenchymal stem cell transplantation
13 Recruiting Measuring Active Microglia in Progressive Multiple Sclerosis
Condition: Secondary Progressive Multiple Sclerosis
Intervention: Radiation: [C11]PK-1195 PET scan
14 Recruiting Safety, Tolerability and Activity Study of Ibudilast in Subjects With Progressive Multiple Sclerosis
Conditions: Multiple Sclerosis, Primary Progressive;   Multiple Sclerosis, Secondary Progressive
Interventions: Drug: ibudilast;   Drug: Placebo
15 Recruiting A Phase 2b/3 Study to Compare Efficacy and Safety of Masitinib to Placebo in the Treatment of Patients With Primary Progressive or Relapse-free Secondary Progressive Multiple Sclerosis
Conditions: Multiple Sclerosis, Secondary Progressive;   Multiple Sclerosis, Primary Progressive;   Multiple Sclerosis, Relapse Free
Interventions: Drug: masitinib;   Drug: placebo
16 Recruiting Double Blind Combination of Rituximab by Intravenous and Intrathecal Injection Versus Placebo in Patients With Low-Inflammatory Secondary Progressive Multiple Sclerosis (RIVITaLISe)
Condition: Multiple Sclerosis
Intervention: Drug: Rituximab
17 Not yet recruiting A Phase 2 Clinical Study in Subjects With Primary Progressive Multiple Sclerosis to Assess the Efficacy, Safety and Tolerability of Two Oral Doses of Laquinimod Either of 0.6 mg/Day or 1.5mg/Day (Experimental Drug) as Compared to Placebo
Condition: Primary Progressive Multiple Sclerosis
Interventions: Drug: Laquinimod;   Drug: Placebo
18 Completed A Study for Patients With Secondary Progressive Multiple Sclerosis
Condition: Secondary Progressive Multiple Sclerosis
Interventions: Drug: dirucotide;   Drug: Placebo
19 Recruiting A Safety and Efficacy Study of Oral Prolonged-Release Fampridine (BIIB041) in Japanese Participants With Multiple Sclerosis
Conditions: Multiple Sclerosis, Remittent Progressive;   Multiple Sclerosis, Primary Progressive;   Relapsing-Remitting Multiple Sclerosis;   Secondary Progressive Multiple Sclerosis;   Multiple Sclerosis
Interventions: Drug: Placebo;   Drug: fampridine (BIIB041)
20 Recruiting A Trial to Compare the Effectiveness of Two Rehabilitation Programs for Multiple Sclerosis Patients
Conditions: Primary Progressive Multiple Sclerosis,;   Secondary Progressive Multiple Sclerosis;   Relapsing-remitting Multiple Sclerosis,;   Demyelinating Autoimmune Diseases,;   Nervous System Diseases
Interventions: Behavioral: Combined program;   Behavioral: Physiotherapy in private practice

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years